Key result
MHC class II expression, specifically HLA-DPA1, was significantly associated with higher progression-free survival (P=0.003) in pediatric adrenocortical tumors.
Why the study?
Does MHC class II expression predict progression-free survival in pediatric adrenocortical tumors?
Cohort (n=63)
Yes
Does MHC class II expression predict progression-free survival in pediatric adrenocortical tumors?
p-value: p=0.003
MHC class II expression by tumor-infiltrating immune cells is an indicator of disease aggressiveness and better progression-free survival in pediatric adrenocortical tumors.
May support MHC class II as a prognostic marker in pediatric adrenocortical tumors; leaves open prospective validation before clinical use.
PURPOSE: Histologic markers that differentiate benign and malignant pediatric adrenocortical tumors are lacking. Previous studies have implicated an association of MHC class II expression with adrenocortical tumor prognosis. Here, we determined the expression of MHC class II as well as the cell of origin of these immunologic markers in pediatric adrenocortical tumor. The impact of MHC class II gene expression on outcome was determined in a cohort of uniformly treated children with adrenocortical carcinomas. EXPERIMENTAL DESIGN: We analyzed the expression of MHC class II and a selected cluster of differentiation genes in 63 pediatric adrenocortical tumors by Affymetrix Human U133 Plus 2.0 or HT HG-U133+PM gene chip analyses. Cells expressing MHC class II were identified by morphologic and immunohistochemical assays. RESULTS: ) and was associated with a higher progression-free survival (PFS) estimate (P = 0.003). Specifically, HLA-DPA1 expression was most significantly associated with PFS after adjustment for tumor weight and stage. HLA-DPA1 was predominantly expressed by hematopoietic infiltrating cells and undetectable in tumor cells in 23 of 26 cases (88%). CONCLUSIONS: MHC class II expression, which is produced by tumor-infiltrating immune cells, is an indicator of disease aggressiveness in pediatric adrenocortical tumor. Our results suggest that immune responses modulate adrenocortical tumorigenesis and may allow the refinement of risk stratification and treatment for this disease. Clin Cancer Res; 22(24); 6247-55.
No takes yet. Share an insight, caveat, or question.
Pinto et al. (2016) conducted a cohort in Pediatric adrenocortical tumors (n=63). MHC class II expression was evaluated on Progression-free survival (PFS) (p=0.003). MHC class II expression, specifically HLA-DPA1, was significantly associated with higher progression-free survival (P=0.003) in pediatric adrenocortical tumors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: